James Alecxih - Aug 10, 2023 Form 3 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Role
President, Device Technology
Signature
/s/ Sean Murphy, Attorney-in-Fact for James Alecxih
Stock symbol
TLSI
Transactions as of
Aug 10, 2023
Transactions value $
$0
Form type
3
Date filed
8/14/2023, 07:02 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TLSI Common Stock 94.8K Aug 10, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 94.8K $10.30 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming an executive officer of the Issuer. The Reporting Person was appointed as an executive officer of the Issuer effective immediately after the effective time of the Merger (as defined in that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended, by and among the Issuer, MTAC Merger Sub, Inc., and TriSalus Operating Life Sciences, Inc.).
F2 Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 20, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F3 Twenty-five percent of the shares subject to the option vest on February 20, 2024, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.